Mar 22, 2023 08:00 AM

Staidson(Beijing) Biopharmaceuticals Co.,Ltd. Posted 197 Million Yuan Net Loss in 2022

By Caixin Automation

Staidson(Beijing) Biopharmaceuticals Co.,Ltd. (舒泰神(北京)生物制药股份有限公司) (300204.SZ) reported a net loss of 197 million yuan in 2022, widening 43.4% year-on-year.

Meanwhile, the company posted 549 million yuan in revenue, down 6% year-on-year.

At the end of the reporting period, it had 1.7 billion yuan in total assets and 315.5 million yuan in total liabilities, with a liability-to-asset ratio of 18.9%.

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Powerful Quake Strikes Off Japan

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

China Business Uncovered Podcast: Brazil’s ‘Very Chinese Moment’

00:00

00:00/00:00

MOST POPULAR

1: Luckin-Backer Centurium Capital to Buy Blue Bottle Coffee From Nestlé

2: Cover Story: How China’s Growing Gig Economy Has Left a Generation Adrift

3: Two Sessions: With 4.5%-5% Growth Target, China Aims to Create Space for Reform

4: First Tanker Crosses Strait of Hormuz Since Iran’s Closure Threat

5: Two Sessions: China’s 2026 Growth Target in Focus as Range Option Looms

SPONSORED

OR